相关实验视频

Updated: Jun 18, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

在早期乳腺癌中,GAIN2试验的整体存活率与强度与量身定制的剂量密集化疗相比

Volker Möbus¹, Hans-Joachim Lück², Ekkehart Ladda³

¹Medizinische Klinik II, Abt. Hämatologie/Onkologie, Universitätsklinikum Frankfurt, Frankfurt, Germany.

NPJ breast cancer

|July 30, 2024

概括

GAIN-2试验发现,强度剂量密集的epirubicin,nab-paclitaxel和cyclophosphamide (iddEnPC) 在早期乳腺癌中改善了病理完整反应 (pCR). 在 iddEnPC 和量身定制的剂量密集方案之间,生存结果是相似的.

科学领域:

在瘤学瘤学.
临床试验临床试验
乳腺癌研究研究乳腺癌研究

背景情况:

高风险的早期乳腺癌需要最佳的辅助和新辅助化疗策略.
为了提高疗效,正在探索强度剂量密集 (idd) 化疗方案.
该GAIN-2试验之前评估了不同的化疗方法.

研究的目的:

从GAIN-2试验中报告病理完整反应 (pCR) 和整体存活率 (OS) 的次要终点.
为了比较强度剂量密集方案 (iddEnPC) 与量身定制剂量密集方案 (dtEC-dtD) 的疗效.
评估pCR对高风险早期乳腺癌患者的生存结果的影响.

主要方法:

随机试验比较了iddd epirubicin,nab-paclitaxel和cyclophosphamide (iddEnPC) 与一个量身定制的剂量密度方案 (dtEC-dtD).
总共有2887名患者随机选择;593人接受了新辅助疗法.
总体队列的中位数随访时间为6.5年,新辅助队列的中位数为5.7年.

主要成果:

两种疗法都显示了可比的5年整体存活率 (90.8%和90.0%).
在ddEnPC治疗方案中,在新辅助剂环境中显示出明显更高的pCR率 (51.2%对42.6%,p=0.045).
获得PCR的患者有改善的5年无侵袭性疾病存活率 (iDFS) 和OS,但总体存活率无论PCR状态如何都是可比的.

结论:

与量身定制的剂量密集疗法 (dtEC-dtD) 相比,强度剂量密集的epirubicin,nab-paclitaxel和cyclophosphamide (iddEnPC) 与更高的病理完整反应 (pCR) 率有关.
尽管pCR有差异,但两种方案的长期整体生存结果相似.
在这种患者群体中,实现pCR是改善无病生存率和整体生存率的重要预测指标.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...